Supplemental Table 4.
Trial Eventsa
| Variable | Trial Event, n |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 2 |
Month 3 |
Month 6 |
Month 12 |
Month 24 |
Month 36 |
Total Events | Total Patients | |||||||
| HR | IR | HR | IR | HR | IR | HR | IR | HR | IR | HR | IR | |||
| MIBC progression | 0 | 0 | 2 | 0 | 5 | 0 | 8 | 0 | 9 | 1 | 4 | 0 | 29 | 29 |
| NMIBC recurrence | 3 | 2 | 6 | 6 | 38 | 20 | 19 | 32 | 23 | 44 | 22 | 18 | 233 | 138 |
| Recurrence grade | 2 | 2 | 6 | 4 | 35 | 14 | 16 | 29 | 17 | 37 | 17 | 17 | 196 | 121 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 3 | 3 |
| Grade 1 | 0 | 1 | 0 | 0 | 4 | 7 | 3 | 11 | 5 | 14 | 0 | 9 | 54 | 36 |
| Grade 2 | 1 | 0 | 3 | 4 | 9 | 7 | 4 | 15 | 7 | 21 | 7 | 7 | 85 | 62 |
| Grade 3 | 1 | 1 | 3 | 0 | 22 | 0 | 7 | 3 | 5 | 2 | 9 | 1 | 54 | 46 |
Abbreviations: EQ-5D = EuroQoL 5 dimension; HR = high-risk (patients); IR = intermediate-risk (patients); MIBC = muscle-invasive bladder cancer; NMIBC = non–muscle-invasive bladder cancer.
a
For cases in which multiple NMIBC recurrences had developed between the EQ-5D and/or annual cost assessments, the analysis set was applied to the recurrence with the highest grade recorded (see the “Materials and Methods” section for details).